Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease
A Randomized, Double-masked, Parallel, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of SJP-0132 Eye Drops Compared With Placebo in Chinese Patients With Dry Eye Disease
Sponsor: Senju Pharmaceutical Co., Ltd.
Listed as NCT06717152, this PHASE3 trial focuses on Dry Eye and remains completed. Sponsored by Senju Pharmaceutical Co., Ltd., it has been updated 6 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jan 2025 — Feb 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Dec 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Senju Pharmaceutical Co., Ltd.
- Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Dalian, China , Guangzhou, China , Guiyang, China , Hangzhou, China , Hengyang, China , Jinan, China and 16 more locations